Data Exclusivity Remains A Top Issue In USTR's 2011 Special 301 Report
This article was originally published in The Pink Sheet Daily
Executive Summary
In its annual report on U.S. trading partners' protection of intellectual property rights, the U.S. Trade Representative also cites the pricing and reimbursement policies of New Zealand and Poland.
You may also be interested in...
R&D For Diseases Of Developing Countries Could Be Driven By Pooled Funds
WHO committee backs use of pooled funds to finance R&D, nixes priority review vouchers and finds no need for data exclusivity. Novartis’ Paul Herrling, a committee member, notes that governments would be responsible for R&D costs.
Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions
As the U.S. enters the eighth round of negotiations over the Trans-Pacific Partnership Agreement, non-government organizations and the generic drug industry are speaking out against intellectual property proposals backed by brand-name pharma.
Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions
As the U.S. enters the eighth round of negotiations over the Trans-Pacific Partnership Agreement, non-government organizations and the generic drug industry are speaking out against intellectual property proposals backed by brand-name pharma.